Phase I trial of Intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa)

被引：4
|
作者：
Galanis, E. [1 ]
Hartmann, L. C. [1 ]
Cliby, W. [1 ]
Peethambaram, P. P. [1 ]
Long, H. J. [1 ]
Kaur, J. S. [1 ]
Haluska, P., Jr. [1 ]
Sloan, J. A. [1 ]
Peng, K. [1 ]
Russell, S. J. [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5538
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase I Clinical Trial of an IL-12 Gene Plasmid Formulated with a Novel Lipopolymeric Gene Delivery System for Intraperitoneal Treatment of Recurrent Ovarian Cancer
    Alvarez, Ronald D.
    Barnes, Mack N.
    McCombs, Connie
    Makhija, Sharmila
    Fewell, Jason
    Lewis, Danny H.
    Anwer, Kursheed
    MOLECULAR THERAPY, 2006, 13 : S425 - S425
  • [32] PHASE I CLINICAL TRIAL OF AUTOLOGOUS T-CELLS GENETICALLY ENGINEERED WITH A CHIMERIC RECEPTOR TO TARGET THE FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) IN PATIENTS WITH RECURRENT OVARIAN CANCER (OVCA)
    Wenham, Robert
    Davila, Marco
    Abate-Daga, Daniel
    McGettigan, Melissa
    Wang, Xuefeng
    Boyle, Theresa
    Garzone, Pamela
    Kumar, Amit
    Conejo-Garcia, Jose
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A702 - A702
  • [33] A Multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene
    Madhusudan, S
    Tamir, A
    Bates, N
    Flanagan, E
    Gore, ME
    Barton, DPJ
    Harper, P
    Seckl, M
    Thomas, H
    Lemoine, NR
    Charnock, M
    Habib, NA
    Lechler, R
    Nicholls, J
    Pignatelli, M
    Ganesan, TS
    CLINICAL CANCER RESEARCH, 2004, 10 (09) : 2986 - 2996
  • [34] REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC).
    Sjoquist, Katrin Marie
    Mileshkin, Linda R.
    Ananda, Sumitra
    Shannon, Catherine M.
    Bowtell, David
    Yip, Sonia
    Espinoza, David
    Goh, Jeffrey C.
    Harrison, Michelle L.
    Plebanski, Magdalena
    Gebski, Val
    Stockler, Martin R.
    Livingstone, Karen
    Tang, Monica
    Friedlander, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] A phase I trial of intraperitoneal EGEN-001, a novel IL-12 gene therapeutic, administered alone or in combination with chemotherapy in patients with recurrent ovarian cancer
    Kendrick, J. E.
    Matthews, K. S.
    Straughn, J. M., Jr.
    Barnes, M. N.
    Fewell, J.
    Anwer, K.
    Alvarez, R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Preclinical Toxicology Assessment of an Oncolytic Measles Virus Armed with H. pylori Immunostimulatory Bacterial Antigen in Preparation for a Phase I Trial in Breast Cancer Patients
    Viker, Kimberly
    Steele, Michael B.
    Iankov, Ianko D.
    Ammayappan, Arun
    Concilio, Susanna C.
    Bolon, Brad
    Jenks, Nathan J.
    Panagioti, Eleni
    Federspiel, Mark J.
    Liu, Minetta C.
    Peng, Kah Whye
    Galanis, Evanthia
    MOLECULAR THERAPY, 2021, 29 (04) : 5 - 5
  • [37] Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in combination: a phase I trial in patients with recurrent ovarian cancer
    Poole, CJ
    Perren, T
    Gawande, S
    Ridderheim, M
    Cook, J
    Jenkins, A
    Roychowdhury, D
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 (02) : 507 - 514
  • [38] Toxicology and Pharmacology Studies on an Indiana Strain Vesicular Stomatitis Virus Expressing the Human Interferon Beta Protein for a Phase I Trial in Patients With Recurrent Hepatocellular Carcinoma
    Myers, R.
    Greiner, S.
    Thompson, J.
    Jenks, N.
    Greenslade, A.
    Mader, E.
    Federspiel, M.
    Russell, S. J.
    Barber, G.
    Rakela, J.
    Borad, M.
    Vile, R.
    Peng, K. W.
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2009, 28 (01) : 60 - 60
  • [39] Phase II trial of intraperitoneal (IP) administration of catumaxomab (C) as consolidation therapy for patients (pts) with relapsed epithelial ovarian cancer (OC) in second or third complete remission: GEICO 1001 study.
    Romero, Ignacio
    Oaknin, Ana
    Angel Arranz, Jose
    Garcia-Martinez, Elena
    Herrero, Ana
    Casado, Antonio
    De Juan, Ana
    Guerra, Eva
    Hernando Polo, Susana
    Santaballa, Ana
    Poveda, Andres
    Gonzalez-Martin, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase I/II Trial of Adipose Tissue Derived Mesenchymal Stem Cell Delivery of a Measles Virus Strain Engineered to Express the Sodium Iodide Symporter in Ovarian Cancer Patients
    Galanis, Evanthia
    Atherton, Pamela J.
    Viker, Kimberly B.
    Federspiel, Mark J.
    Peng, Kah Whye
    Grudem, Megan E.
    Knutson, Keith L.
    Butler, Greg W.
    Dietz, Allan B.
    Erskine, Courtney L.
    Block, Matthew S.
    Hendrickson, Andrea E. Wahner
    Weroha, S. John
    MOLECULAR THERAPY, 2020, 28 (04) : 589 - 589
12345